Literature DB >> 9351559

The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.

D S Smith1, P A Humphrey, W J Catalona.   

Abstract

BACKGROUND: It is not yet known whether screening for the detection of early prostate carcinoma will reduce mortality rates. However, data are available to assess intermediate outcomes from screening, including the performance characteristics of the screening tests and shifts in disease stage.
METHODS: Approximately 30,000 community volunteers (mean age 60 years; <5% nonwhite) were enrolled in 1 of 3 screening studies. Volunteers were screened with PSA or PSA in combination with digital rectal examination at 6-month intervals, and prostatic biopsy was recommended for those with results suspicious for cancer. Based on a first-time screen, the current study reports screening test results, the proportion of men recommended to undergo biopsy, the proportion who actually underwent biopsy, and the carcinoma detection rates for each study, stratified by initial PSA level. The authors also report the pathologic features of screen-detected carcinomas for a subset of men who underwent radical prostatectomy and for whom complete embedding and microscopic examination of the surgical specimen was performed.
RESULTS: Approximately 10% of the volunteers had PSA levels >4.0 ng/mL and 3-10% had digital rectal examination results suspicious for cancer. Overall, 9-20% of volunteers were recommended to undergo biopsy and 8-13% actually underwent the procedure. The positive predictive value for carcinoma detection ranged from 25-33% across studies. In the subset of men for whom surgical specimens were completely embedded, the majority of tumors detected had the clinicopathologic features of significant carcinoma (<10% possibly harmless).
CONCLUSIONS: The intermediate outcomes for screening with PSA and/or PSA in combination with digital rectal examination are encouraging. In community volunteers these screening tests demonstrated reasonable positive predictive value and detected carcinomas at an earlier stage. The majority of screen-detected tumors had the pathologic characteristics of medically significant carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351559

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Guangyun Sun; Ritesh Kaushal; Joshua J Meeks; C Shad Thaxton; Saurav Guha; Carol H Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2007-06-26       Impact factor: 4.132

Review 2.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

3.  Markers of dispute.

Authors:  Virginia Hughes
Journal:  Nat Med       Date:  2009-12       Impact factor: 53.440

4.  Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Authors:  Prodipto Pal; Huifeng Xi; Saurav Guha; Guangyun Sun; Brian T Helfand; Joshua J Meeks; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

5.  Association of genetic and non-genetic risk factors with the development of prostate cancer in Malaysian men.

Authors:  Khamsigan Munretnam; Livy Alex; Nurul Hanis Ramzi; Jagdish Kaur Chahil; I S Kavitha; Nikman Adli Nor Hashim; Say Hean Lye; Sharmila Velapasamy; Lian Wee Ler
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

6.  Disease risk factors identified through shared genetic architecture and electronic medical records.

Authors:  Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

7.  Zinc as an Imaging Biomarker of Prostate Cancer.

Authors:  Su-Tang Lo; André F Martins; Veronica Clavijo Jordan; A Dean Sherry
Journal:  Isr J Chem       Date:  2017-07-31       Impact factor: 3.333

8.  Associations of IgG N-linked oligosaccharide chains and proteases in sera of prostate cancer patients with and without alpha2-macroglobulin deficiency.

Authors:  Yuhsaku Kanoh; Shin Egawa; Shiro Baba; Tohru Akahoshi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 9.  Biosensors: the new wave in cancer diagnosis.

Authors:  Brian Bohunicky; Shaker A Mousa
Journal:  Nanotechnol Sci Appl       Date:  2010-12-30

10.  Prognostic potential of a PSA complex in sera of prostate cancer patients with alpha2-macroglobulin deficiency.

Authors:  Yuhsaku Kanoh; Tadashi Ohara; Shin Egawa; Shiro Baba; Tohru Akahoshi
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.